Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Extra Space Storage, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Extra Space Storage, Inc. trades at $145.13 (market cap $30.41B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays a 4.5% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EXR | |
|---|---|---|
Market Cap | $39.89B | $30.41B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $152.75 |
52-Week Low | $278.09 | $126.67 |
Enterprise Value | $38.15B | $44.21B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Extra Space Storage (EXR) trades at $143.96, up 0.9% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $3.38B and net income of $974M, though profitability margins have moderated from prior peaks. Recent news includes a $550M senior notes offering and the release of its 2025 sustainability report, indicating ongoing capital management and operational focus.
Outlook is mixed: analyst consensus is a Buy with a $155.88 price target, but technical weakness and expense growth pose near-term risks. The stock offers income via a $1.62 dividend, yet investors face headwinds from competitive pressures and potential occupancy declines. Valuation remains elevated with a P/E of 32.35, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
